Cargando…

Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis

BACKGROUND: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine. METHODS: This review article was designed based on PRISMA guidelines. To review the literature, two r...

Descripción completa

Detalles Bibliográficos
Autores principales: Badfar, Gholamreza, Mansouri, Akram, Shohani, Masoumeh, Karimi, Hamid, Khalighi, Zahra, Rahmati, Shoboo, Delpisheh, Ali, Veisani, Yousef, Soleymani, Ali, Azami, Milad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686301/
https://www.ncbi.nlm.nih.gov/pubmed/29201313
http://dx.doi.org/10.22088/cjim.8.4.239
_version_ 1783278764737691648
author Badfar, Gholamreza
Mansouri, Akram
Shohani, Masoumeh
Karimi, Hamid
Khalighi, Zahra
Rahmati, Shoboo
Delpisheh, Ali
Veisani, Yousef
Soleymani, Ali
Azami, Milad
author_facet Badfar, Gholamreza
Mansouri, Akram
Shohani, Masoumeh
Karimi, Hamid
Khalighi, Zahra
Rahmati, Shoboo
Delpisheh, Ali
Veisani, Yousef
Soleymani, Ali
Azami, Milad
author_sort Badfar, Gholamreza
collection PubMed
description BACKGROUND: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine. METHODS: This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SID, Scopus, PubMed, Science Direct, Web of Science and Google Scholar without time limit until May 2017. Cochran's Q test and I(2) index were used to assess the heterogeneity of the studies. The data were analyzed using Comprehensive Meta-Analysis software version 2 and p<0.05 was considered significant. RESULTS: A total of 17 articles involving 1,835 Iranian thalassemia major patients treated with deferoxamine were included in the meta-analysis. The overall prevalence of hearing loss was estimated 27.3% (95% confidence intervals (CI): 19-37.6). The prevalence of sensorineural, conductive and mixed hearing loss was estimated 10.6% (95% CI: 5.7-18.8), 14.6% (95% CI: 10.5-20.6) and 9.1% (95% CI: 5.6-14.6), respectively. No significant differences were noted regarding the relationship hearing loss and mean serum ferritin (P=0.29) and average daily deferoxamine (P=0.30). Meta-regression model showed an increased significance in the prevalence of hearing loss based on the year of studies (p<0.0001). CONCLUSIONS: There is a high prevalence of hearing loss in Iranian thalassemia major patients treated with deferoxamine. Therefore, periodic hearing assessments and regular check-ups after the initiation of chelation therapy are necessary.
format Online
Article
Text
id pubmed-5686301
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-56863012017-12-01 Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis Badfar, Gholamreza Mansouri, Akram Shohani, Masoumeh Karimi, Hamid Khalighi, Zahra Rahmati, Shoboo Delpisheh, Ali Veisani, Yousef Soleymani, Ali Azami, Milad Caspian J Intern Med Review Article BACKGROUND: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine. METHODS: This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SID, Scopus, PubMed, Science Direct, Web of Science and Google Scholar without time limit until May 2017. Cochran's Q test and I(2) index were used to assess the heterogeneity of the studies. The data were analyzed using Comprehensive Meta-Analysis software version 2 and p<0.05 was considered significant. RESULTS: A total of 17 articles involving 1,835 Iranian thalassemia major patients treated with deferoxamine were included in the meta-analysis. The overall prevalence of hearing loss was estimated 27.3% (95% confidence intervals (CI): 19-37.6). The prevalence of sensorineural, conductive and mixed hearing loss was estimated 10.6% (95% CI: 5.7-18.8), 14.6% (95% CI: 10.5-20.6) and 9.1% (95% CI: 5.6-14.6), respectively. No significant differences were noted regarding the relationship hearing loss and mean serum ferritin (P=0.29) and average daily deferoxamine (P=0.30). Meta-regression model showed an increased significance in the prevalence of hearing loss based on the year of studies (p<0.0001). CONCLUSIONS: There is a high prevalence of hearing loss in Iranian thalassemia major patients treated with deferoxamine. Therefore, periodic hearing assessments and regular check-ups after the initiation of chelation therapy are necessary. Babol University of Medical Sciences 2017 /pmc/articles/PMC5686301/ /pubmed/29201313 http://dx.doi.org/10.22088/cjim.8.4.239 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Badfar, Gholamreza
Mansouri, Akram
Shohani, Masoumeh
Karimi, Hamid
Khalighi, Zahra
Rahmati, Shoboo
Delpisheh, Ali
Veisani, Yousef
Soleymani, Ali
Azami, Milad
Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
title Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
title_full Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
title_fullStr Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
title_full_unstemmed Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
title_short Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
title_sort hearing loss in iranian thalassemia major patients treated with deferoxamine: a systematic review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686301/
https://www.ncbi.nlm.nih.gov/pubmed/29201313
http://dx.doi.org/10.22088/cjim.8.4.239
work_keys_str_mv AT badfargholamreza hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT mansouriakram hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT shohanimasoumeh hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT karimihamid hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT khalighizahra hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT rahmatishoboo hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT delpishehali hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT veisaniyousef hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT soleymaniali hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis
AT azamimilad hearinglossiniranianthalassemiamajorpatientstreatedwithdeferoxamineasystematicreviewandmetaanalysis